Literature DB >> 27071490

How we manage persons with hereditary angioedema.

Bruce L Zuraw1,2, Sandra C Christiansen1.   

Abstract

Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder clinically characterized by recurrent attacks of subcutaneous and mucosal swelling that can result in significant morbidity and even mortality. Several novel therapies introduced since 2008 have dramatically transformed the approach to management. In this review we will discuss the current understanding of the pathophysiology of HAE, diagnostic evaluation of recurrent angioedema without urticaria, and the therapeutic approach to HAE. We advocate taking an integrative approach to care in order to normalize the lives of affected patients.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  C1 inhibitor; Hereditary angioedema; Management; bradykinin; treatment

Mesh:

Year:  2016        PMID: 27071490     DOI: 10.1111/bjh.14059

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema.

Authors:  Ting Qiu; Maria J Chiuchiolo; Adele S Whaley; Anthony R Russo; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal; Odelya E Pagovich
Journal:  Allergy       Date:  2019-03-19       Impact factor: 13.146

2.  Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.

Authors:  Anthony J Castaldo; Christian Jervelund; Deborah Corcoran; Henrik B Boysen; Sandra C Christiansen; Bruce L Zuraw
Journal:  Allergy Asthma Proc       Date:  2021-02-13       Impact factor: 2.587

3.  Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.

Authors:  Yi Wang; Jean-Francois Marier; Nastya Kassir; Colin Chang; Patrick Martin
Journal:  Clin Transl Sci       Date:  2020-05-26       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.